Cargando…

Peptidomimetics Therapeutics for Retinal Disease

Ocular disorders originating in the retina can result in a partial or total loss of vision, making drug delivery to the retina of vital importance. However, effectively delivering drugs to the retina remains a challenge for ophthalmologists due to various anatomical and physicochemical barriers in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Parsons, Dylan E., Lee, Soo Hyeon, Sun, Young Joo, Velez, Gabriel, Bassuk, Alexander G., Smith, Mark, Mahajan, Vinit B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995992/
https://www.ncbi.nlm.nih.gov/pubmed/33668179
http://dx.doi.org/10.3390/biom11030339
_version_ 1783670023994212352
author Parsons, Dylan E.
Lee, Soo Hyeon
Sun, Young Joo
Velez, Gabriel
Bassuk, Alexander G.
Smith, Mark
Mahajan, Vinit B.
author_facet Parsons, Dylan E.
Lee, Soo Hyeon
Sun, Young Joo
Velez, Gabriel
Bassuk, Alexander G.
Smith, Mark
Mahajan, Vinit B.
author_sort Parsons, Dylan E.
collection PubMed
description Ocular disorders originating in the retina can result in a partial or total loss of vision, making drug delivery to the retina of vital importance. However, effectively delivering drugs to the retina remains a challenge for ophthalmologists due to various anatomical and physicochemical barriers in the eye. This review introduces diverse administration routes and the accordant pharmacokinetic profiles of ocular drugs to aid in the development of safe and efficient drug delivery systems to the retina with a focus on peptidomimetics as a growing class of retinal drugs, which have great therapeutic potential and a high degree of specificity. We also discuss the pharmacokinetic profiles of small molecule drugs due to their structural similarity to small peptidomimetics. Lastly, various formulation strategies are suggested to overcome pharmacokinetic hurdles such as solubility, retention time, enzymatic degradation, tissue targeting, and membrane permeability. This knowledge can be used to help design ocular delivery platforms for peptidomimetics, not only for the treatment of various retinal diseases, but also for the selection of potential peptidomimetic drug targets.
format Online
Article
Text
id pubmed-7995992
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79959922021-03-27 Peptidomimetics Therapeutics for Retinal Disease Parsons, Dylan E. Lee, Soo Hyeon Sun, Young Joo Velez, Gabriel Bassuk, Alexander G. Smith, Mark Mahajan, Vinit B. Biomolecules Review Ocular disorders originating in the retina can result in a partial or total loss of vision, making drug delivery to the retina of vital importance. However, effectively delivering drugs to the retina remains a challenge for ophthalmologists due to various anatomical and physicochemical barriers in the eye. This review introduces diverse administration routes and the accordant pharmacokinetic profiles of ocular drugs to aid in the development of safe and efficient drug delivery systems to the retina with a focus on peptidomimetics as a growing class of retinal drugs, which have great therapeutic potential and a high degree of specificity. We also discuss the pharmacokinetic profiles of small molecule drugs due to their structural similarity to small peptidomimetics. Lastly, various formulation strategies are suggested to overcome pharmacokinetic hurdles such as solubility, retention time, enzymatic degradation, tissue targeting, and membrane permeability. This knowledge can be used to help design ocular delivery platforms for peptidomimetics, not only for the treatment of various retinal diseases, but also for the selection of potential peptidomimetic drug targets. MDPI 2021-02-24 /pmc/articles/PMC7995992/ /pubmed/33668179 http://dx.doi.org/10.3390/biom11030339 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
Parsons, Dylan E.
Lee, Soo Hyeon
Sun, Young Joo
Velez, Gabriel
Bassuk, Alexander G.
Smith, Mark
Mahajan, Vinit B.
Peptidomimetics Therapeutics for Retinal Disease
title Peptidomimetics Therapeutics for Retinal Disease
title_full Peptidomimetics Therapeutics for Retinal Disease
title_fullStr Peptidomimetics Therapeutics for Retinal Disease
title_full_unstemmed Peptidomimetics Therapeutics for Retinal Disease
title_short Peptidomimetics Therapeutics for Retinal Disease
title_sort peptidomimetics therapeutics for retinal disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995992/
https://www.ncbi.nlm.nih.gov/pubmed/33668179
http://dx.doi.org/10.3390/biom11030339
work_keys_str_mv AT parsonsdylane peptidomimeticstherapeuticsforretinaldisease
AT leesoohyeon peptidomimeticstherapeuticsforretinaldisease
AT sunyoungjoo peptidomimeticstherapeuticsforretinaldisease
AT velezgabriel peptidomimeticstherapeuticsforretinaldisease
AT bassukalexanderg peptidomimeticstherapeuticsforretinaldisease
AT smithmark peptidomimeticstherapeuticsforretinaldisease
AT mahajanvinitb peptidomimeticstherapeuticsforretinaldisease